GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Polaris Group (TPE:6550) » Definitions » Research & Development

Polaris Group (TPE:6550) Research & Development : NT$2,355.20 Mil (TTM As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Polaris Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Polaris Group's Research & Development for the three months ended in Mar. 2025 was NT$549.34 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was NT$2,355.20 Mil.

Polaris Group Research & Development Historical Data

The historical data trend for Polaris Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polaris Group Research & Development Chart

Polaris Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 545.22 554.29 923.97 1,545.38 2,192.47

Polaris Group Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 412.32 476.47 616.65 712.74 549.34

Polaris Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2,355.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaris Group  (TPE:6550) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Polaris Group Research & Development Related Terms

Thank you for viewing the detailed overview of Polaris Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Polaris Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Polaris Group (TPE:6550) » Definitions » Research & Development
Comparable Companies
ROCO:4743 ROCO:6535 ROCO:4728 ROCO:4147 ROCO:6589 ROCO:6547 ROCO:6712 ROCO:4162 ROCO:6617 TPE:6541 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
NO.298, Ruiguang Road, 7th floor, Neihu District, Taipei, TWN
Website
https://www.polarispharma.com
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.

Polaris Group Headlines

No Headlines